We produced synthetic CLDN18.2-PD1/CD28 CAR-T cells to increase the antitumor efficacy of CLDN18.2 CAR-T cell therapy and verified their efficacy and safety in gastric cancer through in vitro and in vivo experiments. This evidence concerns the gene CLDN18 and gastric cancer.